FAIRLANE
Clinical Trial Program
A phase II randomized, double-blind, study of ipatasertib (GDC-0068), an Akt inhibitor, in combination with paclitaxel as neoadjuvant treatment for patients with early stage triple negative breast cancer.
Phase II
Status
Finished
Tumour subtype:
TNBC
Scenario
Neoadjuvant
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Mafalda Oliveira, MD (Hospital Universitari de la Vall d'Hebron de Barcelona)
Steve Isakoff, MD, PhD (MGH Cancer Center, Massachusetts General Hospital)
Sites
CENTRO ONCOLOGICO MD ANDERSON INTERNACIONAL ESPAÑA, COMPLEJO HOSPITALARIO HOSPITAL “SAN PEDRO DE ALCANTARA”, CONSORCIO HOSPITALARIO PROVINCIAL DE CASTELLON, HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL DE FUENLABRADA, HOSPITAL DE SANT JOAN DESPI MOISES BROGGI, HOSPITAL DE TORREVIEJA, HOSPITAL FUNDACIÓN JIMÉNEZ DÍAZ, HOSPITAL SON ESPASES, HOSPITAL SON LLATZER, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI SANT JOAN DE REUS, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO CLÍNICO SAN CARLOS, HOSPITAL UNIVERSITARIO FUNDACIÓN DE ALCORCÓN, HOSPITAL UNIVERSITARIO MADRID SANCHINARRO (CENTRO INTEGRAL ONCOLÓGICO CLARA CAMPAL (CIOCC)), HOSPITAL UNIVERSITARIO QUIRÓN MADRID, HOSPITAL UNIVERSITARIO VIRGEN DE LA MACARENA, HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, HU REY JUAN CARLOS, ICO GIRONA (HOSPITAL DR. JOSEP TRUETA), ICO HOSPITALET (DURAN I REYNALS), HOSPITAL BEATRIZ ANGELO, IPO LISBOA (INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL, EPE), IPO PORTO (INSTITUTO PORTUGUÊS DE ONCOLOGIA DE PORTO FRANCISCO GENTIL, EPE )
